Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof
First Claim
Patent Images
1. A method of suppressing growth of cancer cells comprising the steps of:
- conjugating to a polymer, an anti-angiogenic agent selected from at least one of tetrac, triac and analogs thereof, forming a conjugated anti-angiogenic agent;
encapsulating within the polymer of the conjugated anti-angiogenic agent, at least one chemotherapeutic agent;
administering to a subject in need thereof an amount of the conjugated anti-angiogenic agent, effective for performing at least one function selected from increasing the uptake of chemotherapeutic agents into the cancer cells and inhibiting export mechanisms for chemotherapeutic agents from the cancer cells.
3 Assignments
0 Petitions
Accused Products
Abstract
Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric Nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.
94 Citations
20 Claims
-
1. A method of suppressing growth of cancer cells comprising the steps of:
-
conjugating to a polymer, an anti-angiogenic agent selected from at least one of tetrac, triac and analogs thereof, forming a conjugated anti-angiogenic agent; encapsulating within the polymer of the conjugated anti-angiogenic agent, at least one chemotherapeutic agent; administering to a subject in need thereof an amount of the conjugated anti-angiogenic agent, effective for performing at least one function selected from increasing the uptake of chemotherapeutic agents into the cancer cells and inhibiting export mechanisms for chemotherapeutic agents from the cancer cells. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 17, 18, 19, 20)
-
-
15. A method of increasing the chemosensitivity of cancer cells comprising the steps of:
-
conjugating to a polymer, an anti-angiogenic agent selected from at least one of tetrac, triac and analogs thereof, forming a conjugated anti-angiogenic agent; encapsulating within the polymer of the conjugated anti-angiogenic agent, at least one chemotherapeutic agent; administering to the cancer cells the conjugated anti-angiogenic agent in an amount sufficient to perform at least one function selected from enhancing the uptake of chemotherapeutic agents into the cancer cells, and inhibiting export mechanisms for chemotherapeutic agents from the cancer cells.
-
-
16. A method of treating a patient suffering from the presence of a tumor, comprising administering to said patient an anti-angiogenic agent of tetrac, tetrac analogs, or nanoparticles thereof in an amount effective for enhancing the chemosensitivity of cancer cells, wherein said anti-angiogenic agent is conjugated to a polymer and wherein said anti-angiogenic agent binds to integrin α
- vβ
3 receptor, inhibiting angiogenesis.
- vβ
Specification